Phase II study of cetuximab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer

Phase 2

• Conditions: metastatic colorectal cancer

• Registration Number: JPRN-UMIN000010638
• Lead Sponsor: Japan Clinical Cancer Research Organization

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-05-07
• Study Completion: 2016-11-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Not provided

Exclusion Criteria

1) Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval. 2) Symptomatic brain metastases. 3) Severe infectious disease. 4) Comorbidity or history of interstitial lung disease or pulmonary fibrosis. 5) Comobidity or history of severe heart failure. 6) Sensory alterration or paresthesia interfering with function. 7) Large quanity of pleural, abdominal or cardiac effusion. 8) Severe comobidity (renal failure, liver failure, hypertension, etc.) 9) Prior radiotherapy for primary and metastatic tumors. 10) Men/women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test. 11) Any other cases who are regarded as inadequate for study enrollment by investigators.

Study & Design

• Study Type: Interventional
• Study Design: Not specified